Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn ’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical...
Source: Chinese Medicine - Category: Complementary Medicine Authors: Tags: Review Source Type: research

Related Links:

Researchers at Cleveland Clinic have discovered a relationship between IBD and non-alcoholic liver disease, postulating that immune factors are involved in both the intestinal and liver lesions (see:Studies Reveal Heightened Liver Disease Rates in IBD Patients Immune-mediated factors may be involved). Below is an excerpt from the article but make note of the reference to the use of Explorsys, a research tool owned by IBM:...Cleveland Clinic researchers and their collaborators have found that patients with inflammatory bowel disease (IBD) experience higher rates of nonalcoholic fatty liver disease, nonalcoholic steatohepati...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Diagnostics Electronic Health Record (EHR) Healthcare Information Technology Healthcare Innovations Medical Research Predictive Analytics Preventive Medicine Public Health Source Type: blogs
This study is based on data from IMS® Diagnosis Monitor and included patients who had received a biological drug in dermatology practices due to psoriasis (PSO), gastroenterology practices due to Crohn's disease (CD) or ulcerative colitis (UC), or rheumatology practices due to rheumatoid arthritis (RA) between April 2015 and December 2018. We analyzed 1,748,948 CD/UC-related prescriptions, 3,968,879 RA-related prescriptions, and 7,321,496 PSO-related prescriptions. Of these, 343,263 (19.6%) prescriptions for IBD, 92,343 (16.2%) prescriptions for RA, and 169,573 (6.9%) prescriptions for PSO were for biologicals. The pro...
Source: Biologicals - Category: Biology Source Type: research
Authors: Chou JW, Lai HC, Chang CH, Cheng KS, Feng CL, Chen TW Abstract The incidence and prevalence of inflammatory bowel disease (IBD) are low but increasing in Taiwan. We aimed to investigate the epidemiology and clinical outcomes of IBD in central Taiwan. We retrospectively analyzed patients with IBD diagnosed at our hospital between January 2000 and September 2018. The diagnostic criteria were based on endoscopic and pathologic findings. Clinical characteristics, treatment regimens, and treatment outcomes were analyzed. A total of 190 patients with IBD were enrolled (80 with Crohn's disease (CD) and 110 with u...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
Understanding the burden of Crohn ’s disease (CD) and ulcerative colitis (UC) is important for measuring treatment value. We estimated lifetime healthcare costs incurred by patients with CD or UC by age at diagnosis.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
AbstractIntroductionPulmonary manifestations of inflammatory bowel disease (IBD), albeit not rare, are largely overlooked in clinical practice. The role of exhaled nitric oxide (eNO) as an established biological marker of airway inflammation compels us to use it as a tool to investigate the exact nature of these manifestations.MethodsFractional eNO (FeNO) was measured in multiple flows, and with the use of a mathematical model, alveolar concentration of NO (CANO) and bronchial flux of NO (JawNO) were assessed in 27 patients with IBD [17 with Crohn ’s disease (CD) and 10 with ulcerative colitis (UC)] and in 39 healthy...
Source: Lung - Category: Respiratory Medicine Source Type: research
Abstract BACKGROUND AND AIM: Fecal calprotectin has successfully been widely recommended as a sensitive biomarker of inflammatory bowel diseases (IBD). Recently, we have identified an excellent new fecal biomarker, B-cell activating factor (BAFF), as effective as fecal calprotectin for diagnosing intestinal inflammation. Here in this study, we sought to investigate the potential of fecal BAFF as a screening marker for gastrointestinal inflammation and neoplasms in patients with abdominal discomfort. METHODS: 230 patients with abdominal discomfort were prospectively enrolled into this study and fecal samples w...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
AbstractPrior to the biologic era, the medical management of patients with inflammatory bowel disease (IBD) was dominated by the use of aminosalicylates, corticosteroids, and immunosuppressants. In the past two decades, the advent of biologic agents that target specific components of the immune response has greatly improved the care of patients with Crohn ’s disease and ulcerative colitis (UC). However, not all patients respond or maintain response to biologic therapy and some patients develop adverse events that necessitate treatment discontinuation. Furthermore, sensitization with formation of anti-drug antibodies ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Source: Critical Reviews in Food Science and Nutrition - Category: Nutrition Authors: Source Type: research
MONDAY, July 15, 2019 -- Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease (CD) or ulcerative colitis (UC) while under treatment with etanercept, according to a study published online July 2 in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsThe prevalence of UC and CD in Japan has risen substantially over the past two  decades, and their disease burden requires further examination.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: China Health | Complementary Medicine | Crohn's Disease | Inflammatory Bowel Disease | Ulcerative Colitis